Volume 62, Issue 2, Pages (August 2002)

Slides:



Advertisements
Similar presentations
Volume 62, Pages S12-S22 (December 2002)
Advertisements

Volume 64, Issue 6, Pages (December 2003)
Volume 65, Issue 1, Pages (January 2004)
Volume 54, Issue 5, Pages (November 1998)
Volume 53, Issue 4, Pages (April 1998)
Volume 56, Issue 4, Pages (October 1999)
Volume 54, Issue 3, Pages (September 1998)
Volume 61, Issue 2, (February 2002)
Volume 68, Issue 2, Pages (August 2005)
Volume 60, Issue 2, Pages (August 2001)
Volume 64, Issue 2, Pages (August 2003)
Volume 61, Issue 5, Pages (May 2002)
Volume 55, Issue 5, Pages (May 1999)
Volume 58, Issue 6, Pages (December 2000)
Volume 62, Issue 1, Pages (July 2002)
Volume 66, Issue 5, Pages (November 2004)
Volume 61, Issue 1, Pages (January 2002)
Volume 60, Issue 3, Pages (September 2001)
Volume 56, Issue 6, Pages (December 1999)
Volume 63, Issue 4, Pages (April 2003)
Volume 65, Issue 6, Pages (June 2004)
Volume 62, Issue 3, Pages (September 2002)
Volume 59, Issue 1, Pages (January 2001)
Volume 59, Issue 5, Pages (May 2001)
Volume 63, Issue 5, Pages (May 2003)
Volume 60, Issue 5, Pages (November 2001)
Isotretinoin alleviates renal damage in rat chronic glomerulonephritis
Volume 67, Issue 5, Pages (May 2005)
Volume 63, Issue 2, Pages (February 2003)
Gene transfer of truncated IκBα prevents tubulointerstitial injury
Magnus Åbrink, Eric Larsson, Anders Gobl, Lars Hellman 
Volume 55, Issue 2, Pages (February 1999)
Volume 79, Issue 10, Pages (May 2011)
Volume 60, Issue 6, Pages (December 2001)
Volume 57, Issue 3, Pages (March 2000)
Volume 79, Issue 4, Pages (February 2011)
Volume 56, Issue 3, Pages (September 1999)
Blockade of NFκB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidney  Yee-Yung Ng, Chun-Cheng Hou, Wansheng.
Volume 59, Issue 3, Pages (March 2001)
Volume 66, Issue 5, Pages (November 2004)
Volume 63, Issue 2, Pages (February 2003)
Effect of nitric oxide modulation on TGF-β1 and matrix proteins in chronic cyclosporine nephrotoxicity  Fuad S. Shihab, Hong Yi, William M. Bennett, Takeshi.
Volume 63, Issue 1, Pages (January 2003)
Volume 67, Issue 2, Pages (February 2005)
Volume 58, Issue 2, Pages (August 2000)
Volume 62, Pages S12-S22 (December 2002)
A role for leukotrienes in cyclosporine nephrotoxicity
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis  H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo 
Volume 57, Issue 6, Pages (June 2000)
Volume 62, Issue 3, Pages (September 2002)
Volume 56, Issue 2, Pages (August 1999)
Volume 59, Issue 5, Pages (May 2001)
M.-J. Wu, M.-C. Wen, Y.-T. Chiu, Y.-Y. Chiou, K.-H. Shu, M.-J. Tang 
Volume 65, Issue 6, Pages (June 2004)
Volume 55, Issue 6, Pages (June 1999)
Volume 69, Issue 11, Pages (June 2006)
Volume 64, Issue 3, Pages (September 2003)
Volume 58, Issue 3, Pages (September 2000)
Zinc deficiency further increases the enhanced expression of endothelin-1 in glomeruli of the obstructed kidney  Hiroyuki Yanagisawa, Kazuaki Moridaira,
Volume 58, Issue 5, Pages (November 2000)
Volume 58, Issue 4, Pages (October 2000)
Volume 59, Issue 5, Pages (May 2001)
Volume 56, Issue 6, Pages (December 1999)
Effects of cyclosporine in osteopontin null mice1
Volume 59, Issue 6, Pages (June 2001)
Volume 72, Issue 11, Pages (December 2007)
Volume 58, Issue 6, Pages (December 2000)
Volume 65, Issue 6, Pages (June 2004)
Volume 65, Issue 1, Pages (January 2004)
Volume 56, Issue 4, Pages (October 1999)
Presentation transcript:

Volume 62, Issue 2, Pages 422-433 (August 2002) Angiotensin II regulation of vascular endothelial growth factor and receptors Flt-1 and KDR/Flk-1 in cyclosporine nephrotoxicity  Fuad S. Shihab, William M. Bennett, Jorge Isaac, Hong Yi, Takeshi F. Andoh  Kidney International  Volume 62, Issue 2, Pages 422-433 (August 2002) DOI: 10.1046/j.1523-1755.2002.00452.x Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 1 Histologic changes. Photomicrographs showing the renal cortex of a salt-depleted rat given vehicle (VH; A, B), cyclosporine A (CsA) 15 mg/kg/day (C, D), or a combination of CsA 15 mg/kg/day and losartan 10 mg/kg/day (E, F). VH-treated rats display normal kidney histology (A, B). In rats treated with CsA, extensive interstitial fibrosis and tubular atrophy (C) and afferent arteriolopathy (D) are seen. When both CsA and losartan are given in combination, these changes are markedly reduced (E, F). Trichrome (A, C, E), PAS (B, D, F). Original magnification ×200. Kidney International 2002 62, 422-433DOI: (10.1046/j.1523-1755.2002.00452.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 2 Infiltration by macrophages in chronic CsA nephrotoxicity. Kidney sections from VH-treated (A), CsA-treated (B) and CsA + L-treated (C) rats for 28 days were stained with ED1, an antibody to macrophages. While VH-treated rats had very few macrophages (A), CsA-treated kidneys displayed large numbers of macrophages infiltrating the tubulointerstitium (B). On the other hand, those animals treated with CsA and losartan showed only rare macrophages (C). Original magnification ×400. Kidney International 2002 62, 422-433DOI: (10.1046/j.1523-1755.2002.00452.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 3 Northern blot expression of vascular endothelial growth factor (VEGF) mRNA. Total RNA was isolated from whole cortex at 7 and 28 days and hybridized with a cDNA probe to VEGF. (A) Results of densitometric analysis after correcting for GAPDH mRNA. Symbols are: (□) placebo (VH); (▪) cyclosporine (CsA); () CsA + nilvadipine (N); () CsA + hydralazine-hydrochlorthiazide (HH); () CsA + enalapril (E); () CsA + losartan (L). *P < 0.05 vs. CsA only group. (B) A representative Northern blot. N = 5 to 6 per group. Kidney International 2002 62, 422-433DOI: (10.1046/j.1523-1755.2002.00452.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 4 Vascular endothelial growth factor (VEGF) protein expression by Western blot. Protein was isolated from whole cortex at 7 and 28 days and hybridized with a goat polyclonal anti-mouse VEGF antibody. Results of the densitometric analysis of equal amounts of protein are shown (A). *P < 0.05 vs. CsA only group. Symbols are: () CsA + L; () CsA + E; () CsA + HH; () CsA + N; (▪) CsA; (□) VH. Abbreviations are in Figure 3. (B) Representative Western blot. N = 5 to 6 per group. Kidney International 2002 62, 422-433DOI: (10.1046/j.1523-1755.2002.00452.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 5 Immunohistochemical staining for VEGF: Kidney sections from VH-treated (A), CsA-treated (B) and CsA+L-treated (C) rats for 28 days were stained with an antibody to VEGF. (B) CsA-treated rats exhibited a strong and diffuse tubular epithelial staining. (A) In contrast, the staining for VH-treated rats was faint and non-specific. (C) Treatment with losartan of CsA rats greatly reduces the intensity of VEGF staining. Original magnification ×400. Kidney International 2002 62, 422-433DOI: (10.1046/j.1523-1755.2002.00452.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 6 Northern blot expression of Flt-1 mRNA. Total RNA was isolated from whole cortex at 7 and 28 days and hybridized with a cDNA probe to Flt-1. (A) Results of densitometric analysis after correcting for GAPDH mRNA. Symbols are: (□) VH; (▪) CsA; () CsA + N; () CsA + HH; () CsA + E; () CsA + L. Abbreviations are in Figure 3 legend. (B) Representative Northern blot. N = 5-6 per group. *P < 0.05 vs. CsA only group. Kidney International 2002 62, 422-433DOI: (10.1046/j.1523-1755.2002.00452.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 7 Northern blot expression of KDR/Flk-1 mRNA. Total RNA was isolated from the whole cortex at 7 and 28 days and was hybridized with a cDNA probe to KDR/Flk-1. (A) Results of densitometric analysis after correcting for GAPDH mRNA. Symbols are: (□) VH; (▪) CsA; () CsA + N; () CsA + HH; () CsA + E; () CsA + L. Abbreviations are in Figure 3 legend. (B) Representative Northern blot. N = 5 to 6 per group. *P < 0.05 vs. CsA only group. Kidney International 2002 62, 422-433DOI: (10.1046/j.1523-1755.2002.00452.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 8 Time course for the expression of VEGF and its receptors Flt-1 and KDR/Flk-1. Symbols are: (×) placebo; (▪) CsA; (▴) CsA + N; (♦) CsA + HH; (○) CsA + E; (•) CsA + L. Abbreviations are in Figure 3 legend. N = 5 to 6 per group. Kidney International 2002 62, 422-433DOI: (10.1046/j.1523-1755.2002.00452.x) Copyright © 2002 International Society of Nephrology Terms and Conditions